Literature DB >> 19242528

Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.

A Hiasa1, H Nishikawa, M Hirayama, S Kitano, S Okamoto, H Chono, S S Yu, J Mineno, Y Tanaka, N Minato, I Kato, H Shiku.   

Abstract

Adoptive T-cell transfer of in vitro cultured T cells derived from cancer patients with naturally developed immune responses has met with some success as an immunotherapeutic approach, although only a limited number of patients showed spontaneous immune responses. To find alternative ways, such as cancer-specific T-cell receptor (TCR) gene transfer, in preparation for sufficient numbers of antigen-specific T cells is an important issue in the field of adoptive T-cell therapy. Given the inherent disadvantage of alphabeta TCR transfer to other alphabeta T cells, namely the possible formation of mixed TCR heterodimers with endogenous alpha or beta TCR, we employed gammadelta T cells as a target for retroviral transfer of cancer-specific TCR and examined whether gammadelta T cells were useful as an alternative population for TCR transfer. Although retroviral transduction to gammadelta T cells with TCR alphabeta genes alone, isolated from a MAGE-A4(143-151)-specific alphabeta CD8(+) cytotoxic T lymphocyte (CTL) clone, did not provide sufficient affinity to recognize major histocompatibility (MHC)-peptide complexes due to the lack of CD8 co-receptor, gammadelta T cells co-transduced with TCR alphabeta and CD8 alphabeta genes acquired cytotoxicity against tumor cells and produced cytokines in both alphabeta- and gammadelta-TCR-dependent manners. Furthermore, alphabeta TCR and CD8-transduced gammadelta T cells, stimulated either through alphabeta TCR or gammadelta TCR, rapidly responded to target cells compared with conventional alphabeta T cells, reminiscent of gammadelta T cells. We propose alphabeta TCR-transduced gammadelta T cells as an alternative strategy for adoptive T-cell transfer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242528     DOI: 10.1038/gt.2009.6

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

2.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

3.  Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system.

Authors:  Mohammed S O Tagod; Satoshi Mizuta; Yuki Sakai; Masashi Iwasaki; Kengo Shiraishi; Hiroaki Senju; Hiroshi Mukae; Craig T Morita; Yoshimasa Tanaka
Journal:  J Immunol Methods       Date:  2019-01-14       Impact factor: 2.303

4.  Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.

Authors:  Takeshi Hanagiri; Yoshiki Shigematsu; Koji Kuroda; Tetsuro Baba; Hironobu Shiota; Yoshinobu Ichiki; Yoshika Nagata; Manabu Yasuda; Tomoko So; Mitsuhiro Takenoyama; Fumihiro Tanaka
Journal:  Cancer Sci       Date:  2012-07-06       Impact factor: 6.716

5.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

Review 6.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 7.  Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.

Authors:  Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa
Journal:  J Biomed Biotechnol       Date:  2010-05-05

8.  TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity.

Authors:  Kangxia He; Hongqin You; Yuxia Li; Lianxian Cui; Jianmin Zhang; Wei He
Journal:  Mol Med       Date:  2016-07-26       Impact factor: 6.354

Review 9.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

10.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.